

Sardesai Niranjana
Form 3
January 04, 2012

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

^ Sardesai Niranjana

(Last) (First) (Middle)

11494 SORRENTO VALLEY
ROAD,^ SUITE A

(Street)

SAN DIEGO,^ CA^ 92121

(City) (State) (Zip)

1. Title of Security
(Instr. 4)

Common Stock

2. Date of Event Requiring
Statement

(Month/Day/Year)

01/03/2012

3. Issuer Name and Ticker or Trading Symbol

INOVIO PHARMACEUTICALS, INC. [INO]

4. Relationship of Reporting
Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner

X Officer ___ Other

(give title below) (specify below)

Chief Operating Officer

5. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group
Filing(Check Applicable Line)

X Form filed by One Reporting
Person

___ Form filed by More than One
Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities
Beneficially Owned
(Instr. 4)

66,800

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

D ^

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)

Title

4. Conversion
or Exercise
Price of
Derivative
Security

5. Ownership
Form of
Derivative
Security:
Direct (D)

6. Nature of Indirect
Beneficial
Ownership
(Instr. 5)

Edgar Filing: Sardesai Niranjn - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Common Stock Option (1)	08/28/2006	08/28/2016	Common Stock	132,462	\$ 1.53	D	Â
Common Stock Option (1)	01/05/2007	01/05/2017	Common Stock	24,530	\$ 1.53	D	Â
Common Stock Option (1)	01/18/2007	01/18/2017	Common Stock	14,718	\$ 1.53	D	Â
Common Stock Option (1)	11/01/2007	11/01/2017	Common Stock	73,590	\$ 1.53	D	Â
Common Stock Option (1)	09/12/2008	09/12/2018	Common Stock	29,436	\$ 1.53	D	Â
Common Stock Option (1)	09/12/2008	09/12/2018	Common Stock	19,624	\$ 1.53	D	Â
Common Stock Option (2)	09/30/2009	09/30/2019	Common Stock	120,000	\$ 1.57	D	Â
Common Stock Option (3)	03/11/2011	03/11/2021	Common Stock	120,000	\$ 1.14	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sardesai Niranjn 11494 SORRENTO VALLEY ROAD SUITE A SAN DIEGO, CA 92121	Â	Â	Â Chief Operating Officer	Â

Signatures

/s/ Niranjn
Sardesai

01/04/2012

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Issued upon assumption of outstanding VGX Pharmaceutical Inc. stock options in conjunction with closing of the business combination
- (1) transaction between VGX Pharmaceuticals and Inovio Pharmaceuticals, Inc. on June 1, 2009. As of January 4, 2012, options are fully vested and exercisable.
 - (2) The vesting schedule for the 120,000 options is as follows: 30,000 shares vested on September 30, 2009; 30,000 shares vested on September 30, 2010; 30,000 shares vested on September 30, 2011; 30,000 shares will vest on September 30, 2012.
 - (3) The vesting schedule for the 120,000 options is as follows: 30,000 shares vested on March 11, 2011; 30,000 shares will vest on March 11, 2012; 30,000 shares will vest on March 11, 2013; 30,000 shares will vest on March 11, 2014

Edgar Filing: Sardesai Niranjan - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.